Latest News

Stay up-to-date on the latest developments in the fields of vitreo-retinal disease treatments and ophthalmology in general. Consult our event calendar for an overview of conferences or meetings where you will be able to meet up with ThromboGenics associates. Be sure to check in regularly for the latest ThromboGenics’ press releases or just subscribe to our mailing list to receive regular updates.

Haven’t found what you’re looking for? Take a look at our press release history.

 

 

  • 19 Jul 2018
    ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME)
  • 27 Jun 2018
    ThromboGenics Plans Name Change to “Oxurion”
  • 21 Jun 2018
    ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC
  • 25 May 2018
    ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME)
  • 23 May 2018
    ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018
  • 14 May 2018
    ThromboGenics Presenting Industry Expertise and Developments at Bio€quity Europe and Knowledge for Growth meetings in Ghent, Belgium
  • 9 May 2018
    ThromboGenics Business Update – Q1 2018
  • 27 Apr 2018
    ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combo with anti-VEGF (ranibizumab) for treatment of DME
  • 6 Apr 2018
    ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data supporting therapeutic potential of THR-149
  • 4 Apr 2018
    ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317 for the Treatment of Diabetic Macular Edema (DME)
  • 15 Mar 2018
    ThromboGenics Business Update – FY 2017
  • 30 Jan 2018
    Disclosure in accordance with Belgian Law of 2 May 2007
  • 26 Jan 2018
    NOVARTIS PHARMA AG HOLDING 5.69% OF THROMBOGENICS EQUITY CAPITAL
  • 8 Dec 2017
    ThromboGenics - Patient Enrolment in Phase II CIRCLE Study Evaluating THR-409 (ocriplasmin) for Non-Proliferative Diabetic Retinopathy Discontinued due to Slow Recruitment Rate
  • 8 Nov 2017
    ThromboGenics Strengthens Leadership Team